TY - JOUR T1 - Effect of HPV 16 E6 Oncoprotein Variants on the Alterations of the Proteome of C33A Cells JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 273 LP - 283 DO - 10.21873/cgp.20258 VL - 18 IS - 3 AU - OLGA LILIA GARIBAY-CERDENARES AU - LUZ VICTORIA SÁNCHEZ-MEZA AU - SERGIO ENCARNACIÓN-GUEVARA AU - MAGDALENA HERNÁNDEZ-ORTÍZ AU - GABRIEL MARTÍNEZ-BATALLAR AU - FRANCISCO ISRAEL TORRES-ROJAS AU - MIGUEL ÁNGEL MENDOZA-CATALÁN AU - OSCAR DEL MORAL-HERNÁNDEZ AU - MARCO ANTONIO LEYVA-VÁZQUEZ AU - BERENICE ILLADES-AGUIAR Y1 - 2021/05/01 UR - http://cgp.iiarjournals.org/content/18/3/273.abstract N2 - Background/Aim: The E6 genotypic variants of HPV 16 identified in lesions of women with cervical cancer (CC) in Southern Mexico include the E-G350, AAa, AAc, E-C188/G350, and E-A176/G350. Transcriptomic analysis cells transfected with those variants showed to induce differential expression of the host genes involved in the development of CC. The aim of this work was to understand how the over-expression of the E6 oncoprotein and its variants can induce molecular mechanisms that lead to more aggressive HPV 16 phenotypes in cervical cancer and which proteins could be associated with the process. Materials and Methods: Total extracts from C33A, C33A mock, C33A AAa, C33A E-C188/G350, C33A E-A176/G350, and C33A E-prototype cells were analyzed using 2D electrophoresis, PDQuest software and mass spectrometry. Validation of results was performed through qPCR. Results: Statistically significant differential expression of 122 spots was detected, 12 of the identified proteins were associated with metabolism and metabolic programming. Out of these CCT8, ENO and ALDH1A were further validated. Conclusion: CCT8 and ALDH1A were found to be over-expressed in C33A AAa and C33A E-A176/G350, compared to the E prototype. Both proteins could be associated with a most aggressive phenotype due to their relationship with metabolism, protein folding and stemness, mechanisms associated to E6 that could be useful in the design of new therapies. ER -